EKF Diagnostics Holdings plc: Business Overview, Financials & Competitive Analysis
EKF Diagnostics is engaged in development, manufacture and supply of in-vitro diagnostic (IVD) products, deriving revenue from the manufacture and sale of medical diagnostic equipment and reagents. The company develop...
Cyborg Score thesis
Diversified diagnostics player with global distribution but challenged by modest margins and valuation dynamics in competitive...
Read the full analyst-debate transcript →Get the Latest EKF Diagnostics Holdings plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeEKF Diagnostics Holdings plc Overview
Pro stress-test →EKF Diagnostics is engaged in development, manufacture and supply of in-vitro diagnostic (IVD) products, deriving revenue from the manufacture and sale of medical diagnostic equipment and reagents. The company develops point-of-care diagnostic devices and tests, providing quick, accurate results for healthcare professionals to make rapid decisions at or near the patient's location.
Strategic Profile
Pro stress-test →The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. Its businesses include Point-of-Care, Central Laboratory, Life Sciences, and Contract Manufacturing, serving areas such as diabetes, hematology, infectious diseases, clinical chemistry, and sports medicine.
Competitive Landscape
Pro stress-test →EKF operates in the fragmented in-vitro diagnostics market competing against larger diversified medical device companies (Roche, Abbott, Siemens) in point-of-care diagnostics and against specialized regional players in reagents and analyzers. The company's competitive advantage lies in niche point-of-care and life sciences markets rather than high-volume clinical chemistry.
Industry Context
EKF Diagnostics Holdings plc operates in In-Vitro Diagnostics (IVD) / Medical Devices.
Key facts
Headquarters: Penarth, UK · Revenue: £56.04M · Market cap: £138.61M